A rare case of synchronous multiple primary lung cancer with different responses to gefitinib

Che-Chi Liao; Yu-Sen Lin; Yu-Chao Lin; Chiao-Jen Cheng; Shuo-Chueh Chen

doi:10.1016/j.rmcr.2020.101270

A rare case of synchronous multiple primary lung cancer with different responses to gefitinib

Respir Med Case Rep. 2020 Oct 24:31:101270. doi: 10.1016/j.rmcr.2020.101270. eCollection 2020.

Authors

Che-Chi Liao¹, Yu-Sen Lin^{2

3}, Yu-Chao Lin^{2

4

5}, Chiao-Jen Cheng¹, Shuo-Chueh Chen^{4

6}

Affiliations

¹ Department of Internal Medicine, China Medical University Hospital, Taichung, 404, Taiwan.
² Graduate Institute of Clinical Medical Science, China Medical University, Taichung, 404, Taiwan.
³ Division of Thoracic Surgery, Department of Surgery, China Medical University Hospital, Taichung, 404, Taiwan.
⁴ Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung, 404, Taiwan.
⁵ School of Medicine, China Medical University, Taichung, 404, Taiwan.
⁶ Department of Respiratory Therapy, College of Health Care, China Medical University, Taichung, 404, Taiwan.

Abstract

Differentiating multiple primary lung cancer (MPLC) from lung metastasis is important, and the pathology and gene mutations may be different between the tumors. A lung biopsy to differentiate lesions should be considered, especially when the response of different tumors to treatment is distinct.

Keywords: Gefitinib; Lung cancer; Multiple primary; Synchronous.

Publication types

Case Reports